RNA-TARGETED ANTIMICROBIAL AGENTS

RNA 靶向抗菌剂

基本信息

批准号：
6140010
负责人：
SERGUEI Y GOLOVINE
金额：
$ 10万
依托单位：
PINNACLE PHARMACEUTICALS
依托单位国家：
美国
项目类别：
财政年份：
2000
资助国家：
美国
起止时间：
2000-07-01 至 2001-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/6140010
关键词：
antibiotics drug discovery /isolation enzyme inhibitors high throughput technology method development ribonuclease P

项目摘要

Antibiotics previously effective against pathogenic bacteria are rapidly being compromised by the spread of multiply resistant strains. Pinnacle Pharmaceuticals' platform technology is in the area of RNA metabolism. Through the development of assays that permit the monitoring of these metabolic events, Pinnacle identifies small molecules capable of interrupting RNA metabolism in a pathogen-specific fashion. Preliminary experiments have validated a novel proprietary assay and have led to the identification of natural product extracts active in the assay. Building on these preliminary results, three Specific Aims are proposed: 1. To extend the current assay to a large set of compound libraries in a high-throughput fashion. 2. To purify and identify the active principles from the previously identified positive extracts. 3. To test the hypothesis that the active compounds target molecular events in a manner consistent with the rationale for the assay. PROPOSED COMMERCIAL APPLICATIONS: NONE AVAILABLE

以前对病原菌有效的抗生素正因多重耐药菌株的传播而迅速受到损害。 Pinnacle Pharmaceuticals 的平台技术属于 RNA 代谢领域。通过开发能够监测这些代谢事件的检测方法，Pinnacle 鉴定出了能够以病原体特异性方式中断 RNA 代谢的小分子。初步实验验证了一种新颖的专有测定法，并鉴定了该测定法中具有活性的天然产物提取物。基于这些初步结果，提出了三个具体目标： 1. 以高通量方式将当前检测扩展到大量化合物库。 2.从先前鉴定的阳性提取物中纯化并鉴定活性成分。 3. 检验活性化合物以与测定原理一致的方式靶向分子事件的假设。拟议的商业应用：不可用